“Secukinumab Reduces Endothelial Dysfunction in Subjects with Moderate-to-Severe Plaque Psoriasis Over 52 Weeks: Results of the Exploratory CARIMA Study” (2018) SKIN The Journal of Cutaneous Medicine, 2(S1), p. S20. doi:10.25251/skin.2.supp.20.